# TREAT AD

> **NIH NIH U54** · EMORY UNIVERSITY · 2024 · $8,324,233

## Abstract

PROJECT SUMMARY OVERALL
There is an urgent need for a diverse portfolio of new therapeutic and diagnostic targets for Alzheimer's
disease (AD). To hasten progress towards the national goal of developing an effective treatment for AD by
2025, the NIA has created several initiatives designed to identify new AD drug targets, including the
Accelerating Medicine Partnership for AD (AMP-AD). Although promising, our understanding of most of the
emerging therapeutic hypotheses and nominated targets is not yet sufficient to support their integration into
drug discovery programs. Understanding that the amount of evidence required to support the integration of a
target into a drug discovery pipeline would far surpass the expertise and capabilities of any one group, here we
introduce the Emory-Sage-SGC-Jax TREAT-AD Center. The past decade of activity has conclusively shown
that the open science approach can be used to de-risk new therapeutic modalities, such as the ones emerging
from AMP-AD, to catalyze biological validation of drug targets and to launch new commercial drug discovery
programs. To reinvigorate the AD drug discovery pipeline with a diverse portfolio of well-supported next
generation AD targets supported by evidence from across the research community, Emory-Sage-SGC-Jax
TREAT-AD Center will develop and openly disseminate resources (experimental tools, reagents, probes,
knowledge, data) that can support target validation and drug discovery across a wide variety of independent
evaluations. In Aim 1, we will develop a prioritized set of therapeutic hypotheses and targets. In Aim 2, we will
develop target enabling packages that include high-quality, well-validated reagents and probes. In Aim 3, we
will use validated probes to generate target and therapeutic hypothesis-relevant biological data to guide target
validation and hypothesis testing. In Aim 4, we will rapidly and openly distribute all Center assets – including
probes - to enable characterization and experimental validation of candidate drug targets by any interested
academic and/or commercial investigator.

## Key facts

- **NIH application ID:** 10954111
- **Project number:** 2U54AG065187-06
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Gregory A Cary
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $8,324,233
- **Award type:** 2
- **Project period:** 2019-09-30 → 2029-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10954111

## Citation

> US National Institutes of Health, RePORTER application 10954111, TREAT AD (2U54AG065187-06). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10954111. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*